Biosion has received approval from the FDA for its investigational new drug application concerning BSI-082, an innovative monoclonal antibody targeting SIRPα.

CDR-Life revealed the FDA's approval for clinical trial application for their drug, CDR404, aimed at addressing solid tumor conditions.

Long-term results show Opdivo combined with Yervoy outlasts Sunitinib in survival outcomes for advanced or metastatic kidney cancer patients who haven't received prior treatment over an 8-year period.

Vanda Pharmaceuticals Granted Green Light by FDA to Advance with Experimental Antisense Oligonucleotide Therapy, VCA-894A, for Managing Charcot-Marie-Tooth Disease, Subtype 2S.

Opdivo® (nivolumab) and CABOMETYX® (cabozantinib) Show Long-Term Survival in 4-Year CheckMate-9ER Trial for 1st-Line Advanced RCC.

Scholar Rock Reveals U.S. FDA Approval for Phase 2 Trial Commencement, Testing Apitegromab for Obesity Management.

Sanofi intends to buy Inhibrx, Inc., bringing a promising rare disease candidate targeting Alpha-1 Antitrypsin Deficiency into its portfolio.

Strand Therapeutics recently revealed that the FDA has approved its request to commence a Phase 1 clinical trial, marking the initial human study of STX-001.

Gilead Sciences' EVOKE-01 Phase 3 Trial for Metastatic NSCLC Fails to Achieve Primary Endpoint: A Comparison of Trodelvy and Docetaxel.

Sandoz Finalizes USD 170 Million Purchase of Coherus BioSciences' Biosimilar Drug CIMERLI* (ranibizumab-eqrn) in the US

BioNTech and DualityBio have launched a critical Phase 3 study for their therapeutic agent BNT323/DB-1303, targeting advanced breast cancer.

NK CellTech has received the green light from the Food and Drug Administration (FDA) to initiate clinical trials for its therapy, NK010.